Systemic Juvenile Idiopathic Arthritis (SJIA) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Systemic Juvenile Idiopathic Arthritis (SJIA) Market Outlook

Thelansis’s “Systemic Juvenile Idiopathic Arthritis (SJIA) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Systemic Juvenile Idiopathic Arthritis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Systemic Juvenile Idiopathic Arthritis (SJIA) Overview

Systemic juvenile idiopathic arthritis (SJIA), previously known as Still's disease or systemic juvenile rheumatoid arthritis, is a type of juvenile idiopathic arthritis that initially affects the entire body or "system" before involving the joints. The primary and most frequent symptom is the occurrence of high fevers, often happening once or twice a day, with temperatures reaching 103°F or higher. Arthritis represents the second most common early indication of sJIA, and it may extend to various joints, including the spine (particularly in the neck area), jaw, and hip joints. Compared to other forms of juvenile idiopathic arthritis, sJIA is more severe and poses a more significant challenge for diagnosis and treatment. For many patients, it becomes a lifelong condition that persists into adulthood. The precise cause of sJIA remains unclear, as children with sJIA typically lack autoantibodies in their bloodstream, a common feature in other types of juvenile idiopathic arthritis. One of the most serious potential complications associated with sJIA is a condition known as macrophage activation syndrome (MAS). Although MAS can arise in any rheumatic disease, approximately 80% of cases are linked to sJIA, though the reasons for this correlation are not well understood. Currently, there is currently no cure for sJIA. The standard approach to managing this condition typically commences with the use of nonsteroidal anti-inflammatory drugs (NSAIDs). If this proves insufficient, the next step may involve administering high doses of corticosteroids orally or via intravenous means.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: